The role of lipid signaling in the progression of malignant melanoma

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In the past decades, a vast amount of data accumulated on the role of lipid signaling pathways in the progression of malignant melanoma, the most metastatic/aggressive human cancer type. Genomic studies identified that PTEN loss is the leading factor behind the activation of the PI3K-signaling pathway in melanoma, mutations of which are one of the main resistance mechanisms behind target therapy failures. On the other hand, illegitimate expressions of megakaryocytic genes p12-lipoxyganse, cyclooxygenase-2, and phosphodiestherase-2/autotaxin (ATX) are mostly involved in the regulation of motility signaling in melanoma through various G-protein-coupled bioactive lipid receptors. Furthermore, endocannabinoid signaling can also be a novel paracrine survival factor in melanoma. Last but not least, prenylation inhibitors acting even on mutated small GTP-ases, such as NRAS of melanoma may offer novel therapeutic opportunities. As regards melanoma, the most effective therapy nowadays is immunotherapy, with the resistance mechanisms also possibly involving the lipid signaling activities of melanoma cells, which further supports the idea of their being therapeutic targets.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalCancer and Metastasis Reviews
DOIs
Publication statusAccepted/In press - May 28 2018

Fingerprint

Melanoma
Lipids
Prenylation
Endocannabinoids
Cyclooxygenase 2
Therapeutics
Guanosine Triphosphate
Phosphatidylinositol 3-Kinases
GTP-Binding Proteins
Immunotherapy
Gene Expression
Mutation
Survival
Neoplasms

Keywords

  • Cyclooxygenase
  • Eicosanoid
  • Lipoxygenase
  • Melanoma
  • Phosphodiestherase-2
  • Signaling

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{4c061d2df6bc4cc3a69d814dae9ae2f4,
title = "The role of lipid signaling in the progression of malignant melanoma",
abstract = "In the past decades, a vast amount of data accumulated on the role of lipid signaling pathways in the progression of malignant melanoma, the most metastatic/aggressive human cancer type. Genomic studies identified that PTEN loss is the leading factor behind the activation of the PI3K-signaling pathway in melanoma, mutations of which are one of the main resistance mechanisms behind target therapy failures. On the other hand, illegitimate expressions of megakaryocytic genes p12-lipoxyganse, cyclooxygenase-2, and phosphodiestherase-2/autotaxin (ATX) are mostly involved in the regulation of motility signaling in melanoma through various G-protein-coupled bioactive lipid receptors. Furthermore, endocannabinoid signaling can also be a novel paracrine survival factor in melanoma. Last but not least, prenylation inhibitors acting even on mutated small GTP-ases, such as NRAS of melanoma may offer novel therapeutic opportunities. As regards melanoma, the most effective therapy nowadays is immunotherapy, with the resistance mechanisms also possibly involving the lipid signaling activities of melanoma cells, which further supports the idea of their being therapeutic targets.",
keywords = "Cyclooxygenase, Eicosanoid, Lipoxygenase, Melanoma, Phosphodiestherase-2, Signaling",
author = "J. T{\'i}m{\'a}r and B. Hegedűs and E. R{\'a}s{\'o}",
year = "2018",
month = "5",
day = "28",
doi = "10.1007/s10555-018-9729-x",
language = "English",
pages = "1--11",
journal = "Cancer and Metastasis Reviews",
issn = "0167-7659",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - The role of lipid signaling in the progression of malignant melanoma

AU - Tímár, J.

AU - Hegedűs, B.

AU - Rásó, E.

PY - 2018/5/28

Y1 - 2018/5/28

N2 - In the past decades, a vast amount of data accumulated on the role of lipid signaling pathways in the progression of malignant melanoma, the most metastatic/aggressive human cancer type. Genomic studies identified that PTEN loss is the leading factor behind the activation of the PI3K-signaling pathway in melanoma, mutations of which are one of the main resistance mechanisms behind target therapy failures. On the other hand, illegitimate expressions of megakaryocytic genes p12-lipoxyganse, cyclooxygenase-2, and phosphodiestherase-2/autotaxin (ATX) are mostly involved in the regulation of motility signaling in melanoma through various G-protein-coupled bioactive lipid receptors. Furthermore, endocannabinoid signaling can also be a novel paracrine survival factor in melanoma. Last but not least, prenylation inhibitors acting even on mutated small GTP-ases, such as NRAS of melanoma may offer novel therapeutic opportunities. As regards melanoma, the most effective therapy nowadays is immunotherapy, with the resistance mechanisms also possibly involving the lipid signaling activities of melanoma cells, which further supports the idea of their being therapeutic targets.

AB - In the past decades, a vast amount of data accumulated on the role of lipid signaling pathways in the progression of malignant melanoma, the most metastatic/aggressive human cancer type. Genomic studies identified that PTEN loss is the leading factor behind the activation of the PI3K-signaling pathway in melanoma, mutations of which are one of the main resistance mechanisms behind target therapy failures. On the other hand, illegitimate expressions of megakaryocytic genes p12-lipoxyganse, cyclooxygenase-2, and phosphodiestherase-2/autotaxin (ATX) are mostly involved in the regulation of motility signaling in melanoma through various G-protein-coupled bioactive lipid receptors. Furthermore, endocannabinoid signaling can also be a novel paracrine survival factor in melanoma. Last but not least, prenylation inhibitors acting even on mutated small GTP-ases, such as NRAS of melanoma may offer novel therapeutic opportunities. As regards melanoma, the most effective therapy nowadays is immunotherapy, with the resistance mechanisms also possibly involving the lipid signaling activities of melanoma cells, which further supports the idea of their being therapeutic targets.

KW - Cyclooxygenase

KW - Eicosanoid

KW - Lipoxygenase

KW - Melanoma

KW - Phosphodiestherase-2

KW - Signaling

UR - http://www.scopus.com/inward/record.url?scp=85047659180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047659180&partnerID=8YFLogxK

U2 - 10.1007/s10555-018-9729-x

DO - 10.1007/s10555-018-9729-x

M3 - Article

C2 - 29808460

AN - SCOPUS:85047659180

SP - 1

EP - 11

JO - Cancer and Metastasis Reviews

JF - Cancer and Metastasis Reviews

SN - 0167-7659

ER -